Akiram Therapeutics strengthens board with drug development expertise
Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce the addition of Anna Törner and Peder Walberg to its board of directors. Their combined expertise in drug development and regulatory affairs fortifies the company's position as it advances toward the planned clinical trials of an innovative cancer treatment in 2024. Additionally, both Törner and Walberg will be investing in the company.Akiram Therapeutics has developed [177]Lu-AKIR001, a novel targeted radioimmunotherapy with the potential to become a first-in-class treatment in